Blog & Resources Camargo Blog May 7th, 2013

Merck Uses 505(b)(2) for New Combo

On May 3, 2013 FDA approved Merck’s Liptruzet, which combines the its Zetia (ezetimibe) and atorvastatin – Pfizer’s Lipitor which has gone generic. According to the Merck press release, Liptruzet was approved “for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.”

Of course, Merck had already developed a very similar drug with its own statin, simvastatin, in combination with ezetimibe, in the combination drug Vytorin (since done generic). Thus Liptruzet is a means for Merck to extend its franchise a few more years, on the back of Pfizer’s drug. Readers will note that Pfizer could have used the Merck product to develop the same combination product.

Note: The FDA website states that the approval is a “ New ester, new salt, or other noncovalent derivative” which is incorrect. Hopefully the FDA will correct this.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights